Pharmacyte BiotechPMCB
13F holders, Q1 2026 (March 31)4holders +2
2new positions
0sold out
$0.57avg. 13F price*
At the end of Q1 2026, 4 institutions reported holding Pharmacyte Biotech Inc. (PMCB) in their 13F filings, up 2 from Q4 2025. 2 opened new positions and 0 sold out. The largest holders were Harbour Investments, Inc. ($2), Caldwell Sutter Capital, Inc. ($1) and Fortitude Family Office, LLC ($1).
- Company
- Pharmacyte Biotech Inc.
- CUSIP
- 71715X104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $3 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 4 shares bought, net +4 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Harbour Investments, Inc. | 0.00% | New | 3 | $2 |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 2 | $1 |
| Fortitude Family Office, LLC | 0.00% | New | 1 | $1 |
| Huntington National Bank | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PMCB's weight in each manager's 13F, not the share of Pharmacyte Biotech Inc. the manager owns.